• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of sexual medicine >Efficacy of phosphodiesterase type 5 inhibitor treatment in men with erectile dysfunction and dyslipidemia: a post hoc analysis of the vardenafil statin study.
【24h】

Efficacy of phosphodiesterase type 5 inhibitor treatment in men with erectile dysfunction and dyslipidemia: a post hoc analysis of the vardenafil statin study.

机译：磷酸二酯酶5型抑制剂治疗男性勃起功能障碍和血脂异常的功效：伐地那非他汀类药物研究的事后分析。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: Dyslipidemia occurs often in subjects with erectile dysfunction (ED), but there is little information about how this condition affects ED treatment responses. AIM: To determine whether low-density lipoprotein cholesterol (LDL-C) levels, total cholesterol (TC)/high-density lipoprotein cholesterol (HDL-C) ratio; or the presence of metabolic syndrome influenced efficacy of vardenafil in men with ED and dyslipidemia. METHODS: Post hoc subgroup analysis of a 12-week study of the influence of lipid levels and presence of metabolic syndrome on the efficacy of vardenafil as measured by International Index of Erectile Function-Erectile Function (IIEF-EF) domain score, responses to Sexual Encounter Profile (SEP) SEP2 and SEP3 questions, duration of erection leading to successful intercourse, and erection duration regardless of the answer to SEP3. Lipid values were obtained at study start, after patients had received at least 3 months of therapy with a statin. MAIN OUTCOME MEASURES: Outcomes in subjects with LDL-C < 100, > or = 100 to < 130, or > or = 130 mg/dL [< 2.59, > or = 2.59 to < 3.36, or > or = 3.36 mmol/L]; TC/HDL-C ratio < 3.5 vs. > or = 3.5, and presence or absence of metabolic syndrome. RESULTS: Vardenafil improved all endpoints evaluated compared with placebo in all subgroups, however, nominally significant treatment by subgroup interaction terms did not follow a distinct pattern. Increasing LDL-C (P = 0.033), but not TC/HDL-C ratio or metabolic syndrome, was associated with an increase in treatment response measured by the IIEF-EF domain score. Responses to SEP3 were nominally influenced by LDL-C levels (P = 0.019), but were not significantly influenced by TC/HDL-C ratio, or the metabolic syndrome. Only higher TC/HDL-C ratios (> or = 3.5) were associated with larger treatment differences in duration of erection leading to successful intercourse (P = 0.028). CONCLUSIONS: Vardenafil was effective in men with dyslipidemia regardless of LDL-C levels, TC/HDL-C ratio, and/or presence of metabolic syndrome. Despite the known presence of ED and dyslipidemia, other cardiovascular risk factors were apparently not aggressively managed.
机译：简介：血脂异常常发生于勃起功能障碍（ED）的受试者中，但是关于这种情况如何影响ED治疗反应的信息很少。目的：确定低密度脂蛋白胆固醇（LDL-C）水平，总胆固醇（TC）/高密度脂蛋白胆固醇（HDL-C）之比;或代谢综合征的存在影响了伐地那非对ED和血脂异常男性的疗效。方法：通过对国际勃起功能-勃起功能指数（IIEF-EF）评分，对性反应的测量，对血脂水平和代谢综合征的存在对伐地那非疗效的影响进行的为期12周的研究的事后亚组分析遭遇档案（SEP）SEP2和SEP3问题，导致成功性交的勃起持续时间以及勃起持续时间，与SEP3的答案无关。患者接受他汀类药物治疗至少3个月后，才在研究开始时获得血脂值。主要观察指标：LDL-C <100，>或= 100至<130，或>或= 130 mg / dL [<2.59，>或= 2.59至<3.36，或>或= 3.36 mmol / L ]; TC / HDL-C比率<3.5 vs.>或= 3.5，以及是否存在代谢综合征。结果：与所有安慰剂组相比，伐地那非在所有亚组中改善了所有评估的终点，但是，亚组相互作用项名义上显着的治疗并未遵循明显的模式。 LDL-C（P = 0.033）升高，但TC / HDL-C比例或代谢综合征不升高，与IIEF-EF域评分所衡量的治疗反应增加有关。对SEP3的反应名义上受LDL-C水平的影响（P = 0.019），但不受TC / HDL-C比值或代谢综合征的影响。只有较高的TC / HDL-C比（>或= 3.5）与勃起持续时间较大的治疗差异相关，才能成功进行性交（P = 0.028）。结论：伐地那非对血脂异常的男性有效，无论LDL-C水平，TC / HDL-C比率和/或是否存在代谢综合征。尽管已知存在ED和血脂异常，但显然并未积极控制其他心血管危险因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号